In conclusion, the present findings demonstrate that treatment with pazopanib amended the cognitive functions, modulated the AD-associated histopathological alterations, diminished the AD hallmarks (p-Tau and Aβ plaques), and mitigated neuroinflammation in D-Gal/OVX rat model of AD. The gene discussed is MAPT; the disease is Alzheimer disease.